Drosophila tools and assays for the study of human diseases

B Ugur, K Chen, HJ Bellen - Disease models & mechanisms, 2016 - journals.biologists.com
Many of the internal organ systems of Drosophila melanogaster are functionally analogous
to those in vertebrates, including humans. Although humans and flies differ greatly in terms …

[HTML][HTML] TCF4-mediated Fuchs endothelial corneal dystrophy: Insights into a common trinucleotide repeat-associated disease

MP Fautsch, ED Wieben, KH Baratz… - Progress in retinal and …, 2021 - Elsevier
Fuchs endothelial corneal dystrophy (FECD) is a common cause for heritable visual loss in
the elderly. Since the first description of an association between FECD and common …

Drosophila Heart as a Model for Cardiac Development and Diseases

A Souidi, K Jagla - Cells, 2021 - mdpi.com
The Drosophila heart, also referred to as the dorsal vessel, pumps the insect blood, the
hemolymph. The bilateral heart primordia develop from the most dorsally located …

Therapeutic potential of AntagomiR-23b for treating myotonic dystrophy

E Cerro-Herreros, I González-Martínez… - … Therapy-Nucleic Acids, 2020 - cell.com
Myotonic dystrophy type 1 (DM1) is a chronically debilitating, rare genetic disease that
originates from an expansion of a noncoding CTG repeat in the dystrophia myotonica …

[HTML][HTML] Myotonic dystrophy: candidate small molecule therapeutics

P Konieczny, E Selma-Soriano, AS Rapisarda… - Drug discovery today, 2017 - Elsevier
Highlights•Up to 34 drug candidates identified in the last few years.•Drug screening methods
available at all levels of complexity (computational to in vivo).•Translational research has …

Cardiac pathology in myotonic dystrophy type 1

MS Mahadevan, RS Yadava, M Mandal - International journal of …, 2021 - mdpi.com
Myotonic dystrophy type 1 (DM1), the most common muscular dystrophy affecting adults and
children, is a multi-systemic disorder affecting skeletal, cardiac, and smooth muscles as well …

[HTML][HTML] RNA-mediated therapies in myotonic dystrophy

SJ Overby, E Cerro-Herreros, B Llamusi, R Artero - Drug discovery today, 2018 - Elsevier
Highlights•RNA medicine shows promise in DM1 therapeutics by targeting toxic CUG
expansions.•Restoring function of Muscleblind-like proteins is especially important in …

Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3′UTR RNA

RS Yadava, Q Yu, M Mandal, F Rigo… - Human molecular …, 2020 - academic.oup.com
Abstract Myotonic dystrophy type 1 (DM1), the most common adult muscular dystrophy, is an
autosomal dominant disorder caused by an expansion of a (CTG) n tract within the 3 …

Small molecules which improve pathogenesis of myotonic dystrophy type 1

M López-Morató, JD Brook… - Frontiers in neurology, 2018 - frontiersin.org
Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in adults for which
there is currently no treatment. The pathogenesis of this autosomal dominant disorder is …

Strategies to obtain encapsulation and controlled release of pentamidine in mesoporous silica nanoparticles

E Peretti, I Miletto, B Stella, F Rocco, G Berlier… - Pharmaceutics, 2018 - mdpi.com
Pentamidine (PTM), an antiprotozoal agent used in clinics as pentamidine isethionate salt
(PTM-S), recently showed high potential also for the treatment of cancer and myotonic …